Pharmasinthesis

History

2023: Ecuador Market Entry

On July 25, 2023, Pharmasintez Group of Companies announced the receipt of seven marketing authorizations in Ecuador for drugs for the treatment of diabetes mellitus, HIV, as well as for the treatment of malignant neoplasms (chemotherapy drugs), which entitle the import and distribution of drugs in the country.

The drugs will be produced at the Pharmasintez-Nord, Pharmasintez-Tyumen sites and the Irkutsk plant of Pharmasintez JSC.

As of July 2023, Pharmasintez Group of Companies has registered more than 100 drugs in the CIS and Latin America.

Not so long ago, the company received marketing authorizations in the Dominican Republic for the supply of three anticancer drugs manufactured by Pharmasintez-Nord. Entering Ecuador was a step for the company to increase its presence in the market of the Latin American region. As of July 2023, active work is also being carried out with other large countries in the region. We see the potential in cooperation with Latin America, first of all, in a fairly large number of friendly countries that are part of it, with which historically constructive relations have developed in the region, - said Nikita Punia, executive director of Farmasintez Group of Companies.

In July 2023, the Pharmasintez-Nord research and production complex, which is part of the Pharmasintez group of companies, successfully passed the inspection of the Syrian Ministry of Health for compliance with GMP standards and received official permission to supply manufactured drugs to the territory of the Syrian Arab Republic.

2022: Pharmasintez invests 1 billion rubles in the production of bronchodilators in Irkutsk

In mid-June 2022, it became known that Farmasintez invested about 1 billion rubles in the production of bronchodilators (drugs that relieve the symptoms of bronchospasm and are used in the treatment bronchial asthma and chronic obstructive disease) lungs in the Irkutsk region. According to the press service of the regional government, within the framework of the project, two sites are planned for the production of hormonal and non-hormonal drugs.

It is expected that the volume of production will be 136 million capsules with powder for inhalation and 867 thousand aerosols for inhalation per year. The receipt of products into circulation is scheduled for the first quarter of 2024.

Pharmasintez invests 1 billion rubles in the production of bronchodilators in Irkutsk

An agreement on socio-economic cooperation is already in force between the government of the Irkutsk region and Farmasintez, and the signed document has become its addition. Under the agreement, Pharmasintez participates in social events in the region, provides charitable assistance to those in need, and also provides material support to Irkutsk State University (ISU), Irkutsk National Research Technical University (IRNIT) and the Institute of Chemistry named after Favorsky Siberian Branch of the Russian Academy of Sciences.

In June 2022, Pharmasintez also announced its intention to launch the production of hormonal drugs at its plant in the Tyumen region. Investments in this project will amount to more than 4 billion rubles. The production line will appear in the summer of 2022.

By mid-June 2022, Pharmasintez is one of the largest manufacturers of socially significant drugs in Russia, as well as a developer of innovative drugs. The company's drugs are presented in the main therapeutic areas, such as tuberculosis, HIV, oncology, diabetes mellitus, hepatitis. The group's portfolio includes more than 170 products. The company's production sites are located in Irkutsk, Ussuriysk, St. Petersburg, Bratsk and Tyumen.^[1]

Notes

Investing 0.5 billion rubles in an intravenous nutrition plant

Pharmasintez invests 0.5 billion rubles in the East Farm intravenous nutrition plant in Ussuriysk. The group announced this on February 16, 2022. Read more here.